If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

The state auditor report found poor record keeping and a lack of therapy to accompany psychotropic medications.

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to ...

Management of adverse events is a major concern of clinicians who use antipsychotic drugs. The incidence of motor side effects is dose dependent. Atypical antipsychotic drugs are less likely to ...

“Regional variations exist in antipsychotic and antidementia medication use among nursing home residents with dementia, suggesting the need for evidence-based protocols to guide the use of these ...

They can be caused by an unmet need – for example, hunger, thirst or discomfort – or a health problem such as an infection. People with these symptoms are often prescribed antipsychotic drugs ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

More information: Lena Feber et al, Antipsychotic Drugs and Cognitive Function, JAMA Psychiatry (2024). DOI: 10.1001/jamapsychiatry.2024.2890 ...

Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by ...